Tofogliflozin - Chugai Pharmaceutical

Drug Profile

Tofogliflozin - Chugai Pharmaceutical

Alternative Names: Apleway; CSG452; Deberza; R 7201; RG 7201; RO4998452; Tofogliflozin hydrate

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Kowa; Osaka University School of Medicine; Sanofi K.K.
  • Class Antihyperglycaemics; Benzhydryl compounds; Benzofurans; Glucosides; Small molecules; Spiro compounds
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Atherosclerosis

Most Recent Events

  • 01 Mar 2017 Phase-II clinical trials in Type-2 diabetes mellitus (Adjunctive treatment, Treatment-experienced) in Japan (PO) (UMIN000026161)
  • 03 Jan 2017 Phase-II clinical trials in Type-2 diabetes mellitus in European Union, USA (PO)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top